Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner

Cell Death and Differentiation

Volumn 17, Issue 10, 2010, Pages 1645-1654

  Probst, B L ^a   Liu, L ^a   Ramesh, V ^a   Li, L ^a   Sun, H ^a   Minna, J D ^b   Wang, L ^a  

^a Joyant Pharmaceuticals   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

apoptosis; cancer; chemotherapeutics; Smac mimetics; TNF

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; JP1010; JP1400; PACLITAXEL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; GENOTOXICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AMINOBENZOIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; OLIGOPEPTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77956712168     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.44     Document Type: Article

References (25)

1. Gorlick R, Bertino J. Drug Resistance in colon cancer. Semin Oncol 1999; 26: 606-611.
2. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-64.
3. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885.
4. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003; 8: 67-77.
5. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
6. Zhou H, Li Y, Liu X, Wang X. An APAF-1, cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549-11556.
7. Verhagen A, Coulson E, Vaux DL. Inhibitor or apoptosis proteins and their relatives: IAPS and other BIRPS. Genome Biol 2001; 2: 3009.
8. Ashkenazi A, Dixit V. Death Receptors: signaling and modulation. Science 1998; 281: 1305-1308.
9. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science 2004; 305: 1471-1474.
10. Galban S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A et al. Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochem J 2009; 417: 765-771.
11. Sun H, Nikolovska-Coleska Z, Lu J, Qiu S, Yang CY, Gao W et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 2006; 49: 7916-7920.
12. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
13. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
14. Wang L, Du F, Wang X. TNF-a induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
15. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
16. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68: 9384-9393.
17. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kB response. Cell Death Differ 2006; 13: 773-784.
18. Brzoskz K, Szumiel I. Signaling loops and linear pathways: NF-kB activation in response to genotoxic stress. Mutagenesis 2009; 24: 1-8.
19. Hickman J. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A: 921-926.
20. Raff M. Social controls on cell survival and cell death. Nature 1993; 356: 397-400.
21. Kaufman H, Wolchok J. General Principles of Tumor Immunotherapy. Sprinter: Dordrecht, The Netherlands, 2007.
22. Estevam FR, Augusto SF, Rodrigues SA, Pinheiro MR, Monteiro AF. Apoptosis and production of TNF-alpha by tumor-associated inflammatory cells in histological grade III breast cancer. Cancer Immunol Immunother 2005; 54: 671-676.
23. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 714-720.
24. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of cIAP1 and cIAP2 but not that of xIAP and livin in HeLa cells. J Biol Chem 2004; 279: 16963-16970.
25. Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li YM et al. A dimeric Smac/DIABLO peptide directly relieves caspase-3 inhibition by xIAP. J Biol Chem 2007; 282: 30718-30727.